CN116018352A - 一种抗IgE的工程化抗体及其应用 - Google Patents

一种抗IgE的工程化抗体及其应用 Download PDF

Info

Publication number
CN116018352A
CN116018352A CN202180049003.2A CN202180049003A CN116018352A CN 116018352 A CN116018352 A CN 116018352A CN 202180049003 A CN202180049003 A CN 202180049003A CN 116018352 A CN116018352 A CN 116018352A
Authority
CN
China
Prior art keywords
amino acid
antigen binding
binding protein
following positions
acid mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049003.2A
Other languages
English (en)
Chinese (zh)
Inventor
邓俗俊
顾春银
刘小五
曹晓丹
刘培培
张建建
潘忠宗
肖政
王学萍
郭海兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiyu Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Jiyu Pharmaceutical Technology Co ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiyu Pharmaceutical Technology Co ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jiyu Pharmaceutical Technology Co ltd
Publication of CN116018352A publication Critical patent/CN116018352A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180049003.2A 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用 Pending CN116018352A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020106630293 2020-07-10
CN202010663029 2020-07-10
CN2021107509597 2021-07-01
CN202110750959 2021-07-01
PCT/CN2021/105620 WO2022007965A1 (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Publications (1)

Publication Number Publication Date
CN116018352A true CN116018352A (zh) 2023-04-25

Family

ID=79552269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049003.2A Pending CN116018352A (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Country Status (11)

Country Link
US (1) US20230250191A1 (cg-RX-API-DMAC7.html)
EP (1) EP4180454A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023541217A (cg-RX-API-DMAC7.html)
KR (1) KR20230042030A (cg-RX-API-DMAC7.html)
CN (1) CN116018352A (cg-RX-API-DMAC7.html)
AU (1) AU2021306786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185192A1 (cg-RX-API-DMAC7.html)
IL (1) IL299747A (cg-RX-API-DMAC7.html)
TW (1) TWI896700B (cg-RX-API-DMAC7.html)
WO (1) WO2022007965A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268176A (zh) * 1997-07-02 2000-09-27 基因技术股份有限公司 改进的抗lgE抗体以及改进多肽的方法
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
CN109379892A (zh) * 2016-06-10 2019-02-22 Ucb生物制药私人有限公司 抗-IgE抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
EP4342541A3 (en) * 2017-04-07 2024-07-03 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP3788078A4 (en) * 2018-05-04 2022-03-02 Allakos Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268176A (zh) * 1997-07-02 2000-09-27 基因技术股份有限公司 改进的抗lgE抗体以及改进多肽的方法
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
CN109379892A (zh) * 2016-06-10 2019-02-22 Ucb生物制药私人有限公司 抗-IgE抗体

Also Published As

Publication number Publication date
US20230250191A1 (en) 2023-08-10
EP4180454A4 (en) 2024-10-02
KR20230042030A (ko) 2023-03-27
IL299747A (en) 2023-03-01
TWI896700B (zh) 2025-09-11
JP2026071342A (ja) 2026-04-28
WO2022007965A1 (zh) 2022-01-13
CA3185192A1 (en) 2022-01-13
EP4180454A9 (en) 2023-07-26
EP4180454A1 (en) 2023-05-17
AU2021306786A1 (en) 2023-02-16
BR112023000400A2 (pt) 2023-03-21
JP2023541217A (ja) 2023-09-29
TW202214703A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
Gebauer et al. Engineered protein scaffolds as next-generation antibody therapeutics
ES2309167T3 (es) Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
JP5901522B2 (ja) 製造性の向上した変異免疫グロブリン
CN102405232B (zh) 改良的抗血清清蛋白结合变体
CN118063619A (zh) 工程化的异源二聚体蛋白质
JP2010522701A5 (cg-RX-API-DMAC7.html)
US20250297033A1 (en) Bispecific antibody for membrane clearance of target receptors
CN102405233B (zh) 改良的抗血清清蛋白结合变体
JP2024507540A5 (cg-RX-API-DMAC7.html)
CN103649118A (zh) 双特异性结合剂
CN101218251A (zh) 异二聚体蛋白结合组合物
TW201620935A (zh) 基於vl和vнн可變區衍生物的高親和力抗聚集抗體
WO2021147941A1 (zh) 一种bcma结合蛋白及其制备方法和应用
JP2026071342A5 (cg-RX-API-DMAC7.html)
JP2003518391A (ja) エピトープに結合可能な蛋白質の変異体のライブラリーから発達した結合メンバーを選抜するために天然型エピトープを使用する方法
EP3666897B1 (en) Super versatile method for presenting cyclic peptide on protein structure
RU2006111579A (ru) Антитела к рецептору интерлейкина-1 и их применение
WO2022166728A1 (zh) 双特异性抗体
JPWO2020027224A1 (ja) 新たな結合特異性を抗体に付与する超汎用法
CA2711882C (en) Improved humanized anti-human .alpha.9-integrin antibody
CN108484770A (zh) 重组大鼠抗小鼠cd4单克隆抗体,制备方法和应用
JP2023541217A5 (cg-RX-API-DMAC7.html)
CN118922442A (zh) 一种抗cd3抗体及其制备方法和用途
TW202144403A (zh) 一種辨識hpv16的高親和力tcr
TW202144402A (zh) 辨識afp抗原的高親和力tcr

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088122

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250331

Address after: 201315, 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai

Applicant after: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: 201203 No. 1118 HaLei Road, pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant before: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd.

Country or region before: China

Applicant before: JIANGXI JEMINCARE GROUP Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 201315, 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai

Applicant after: Shanghai Jiyu Pharmaceutical Technology Co., Ltd.

Address before: 1st Floor, No. 2, Lane 535, Huanqiao Road, Pudong New Area, Shanghai

Applicant before: Shanghai Jiyu Pharmaceutical Technology Co.,Ltd.

Country or region before: China